Natus Medical Incorporated
NTUS · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Revenue | $473,438 | $415,684 | $495,175 | $530,891 |
| % Growth | 13.9% | -16.1% | -6.7% | – |
| Cost of Goods Sold | $199,758 | $199,153 | $203,467 | $226,876 |
| Gross Profit | $273,680 | $216,531 | $291,708 | $304,015 |
| % Margin | 57.8% | 52.1% | 58.9% | 57.3% |
| R&D Expenses | $56,306 | $61,296 | $58,733 | $61,482 |
| G&A Expenses | $52,753 | $49,113 | $59,649 | $68,699 |
| SG&A Expenses | $168,767 | $156,395 | $188,758 | $205,379 |
| Sales & Mktg Exp. | $116,014 | $107,282 | $129,109 | $136,680 |
| Other Operating Expenses | $17,129 | $15,224 | $15,144 | $24,485 |
| Operating Expenses | $242,202 | $232,915 | $262,635 | $291,346 |
| Operating Income | $21,227 | -$20,193 | -$15,666 | -$24,562 |
| % Margin | 4.5% | -4.9% | -3.2% | -4.6% |
| Other Income/Exp. Net | -$1,872 | -$1,872 | -$5,591 | -$7,698 |
| Pre-Tax Income | $19,355 | -$22,065 | -$21,257 | -$32,260 |
| Tax Expense | $6,178 | -$5,452 | -$5,586 | -$9,325 |
| Net Income | $13,177 | -$16,613 | -$15,671 | -$22,935 |
| % Margin | 2.8% | -4% | -3.2% | -4.3% |
| EPS | 0.39 | -0.49 | -0.47 | -0.69 |
| % Growth | 179.6% | -4.3% | 31.9% | – |
| EPS Diluted | 0.39 | -0.49 | -0.47 | -0.69 |
| Weighted Avg Shares Out | 33,974 | 33,562 | 33,696 | 33,111 |
| Weighted Avg Shares Out Dil | 33,974 | 33,562 | 33,696 | 33,111 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $11 | $250 | $334 |
| Interest Expense | $1,872 | $3,656 | $4,941 | $6,794 |
| Depreciation & Amortization | $28,091 | $28,115 | $30,722 | $33,863 |
| EBITDA | $49,318 | $9,706 | $14,406 | $8,397 |
| % Margin | 10.4% | 2.3% | 2.9% | 1.6% |